Evaluation of Mycoplasma inactivation during production of biologics: egg-based viral vaccines as a model.
Although mycoplasmas are generally considered to be harmless commensals, some mycoplasma species are able to cause infections in pediatric, geriatric, or immunocompromised patients. Thus, accidental contamination of biologics with mycoplasmas represents a potential risk for the health of individuals who receive cell-derived biological and pharmaceutical products. To assess the efficiency of inactivation of mycoplasmas by the agents used in the manufacture of egg-derived influenza vaccines, we carried out a series of experiments aimed at monitoring the viability of mycoplasmas spiked into both chicken allantoic fluid and protein-rich microbiological media and then treated with beta-propiolactone, formalin, cetyltrimethylammonium bromide, Triton X-100, and sodium deoxycholate, which are agents that are commonly used for virus inactivation and disruption of viral particles during influenza vaccine production. Twenty-two mycoplasma species (with one to four strains of each species) were exposed to these inactivating agents at different concentrations. The most efficient inactivation of the mycoplasmas evaluated was observed with either 0.5% Triton X-100 or 0.5% sodium deoxycholate. Cetyltrimethylammonium bromide at concentrations of >or=0.08% was also able to rapidly inactivate (in less than 30 min) all mycoplasmas tested. In contrast, negligible reductions in mycoplasma titers were observed with 0.0125 to 0.025% formaldehyde. However, increasing the concentration of formaldehyde to 0.1 to 0.2% improved the mycoplasmacidal effect. Incubation of mycoplasmas with 0.1% beta-propiolactone for 1 to 24 h had a marked mycoplasmacidal effect. A comparison of the mycoplasma inactivation profiles showed that strains of selected species (Mycoplasma synoviae, Mycoplasma gallisepticum, Mycoplasma orale, Mycoplasma pneumoniae, and Acholeplasma laidlawii) represent a set of strains that can be utilized to validate the effectiveness of mycoplasma clearance obtained by inactivation and viral purification processes used for the manufacture of an inactivated egg-based vaccine.
David
Selwyn A Wilson
SA
Division of Viral Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, HFM-470, Rockville, Maryland 20852, USA.
Volokhov
Dmitriy V
DV
Ye
Zhiping
Z
Chizhikov
Vladimir
V
D000128:Acholeplasma laidlawii; D000818:Animals; D000077286:Cetrimonium; D002593:Cetrimonium Compounds / Q000737:chemistry; D002645:Chickens; D003840:Deoxycholic Acid / Q000737:chemistry; D004531:Eggs / Q000821:virology; D005557:Formaldehyde / Q000737:chemistry; D050296:Microbial Viability; D008954:Models, Biological; D009174:Mycoplasma / Q000302:isolation & purification; D045686:Mycoplasma gallisepticum; D009177:Mycoplasma pneumoniae; D045805:Mycoplasma synoviae; D017830:Octoxynol / Q000737:chemistry; D011420:Propiolactone / Q000737:chemistry; D015164:Vaccines, Inactivated; D014765:Viral Vaccines
D002593:Cetrimonium Compounds; D015164:Vaccines, Inactivated; D014765:Viral Vaccines; D003840:Deoxycholic Acid; D005557:Formaldehyde; D011420:Propiolactone; D017830:Octoxynol; D000077286:Cetrimonium